femring- estradiol acetate ring
allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d - femring is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to femring - known liver impairment or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy femring should not be used during pregnancy [ see contraindications (4) ] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. femring should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectabl
femring- estradiol acetate ring
physicians total care, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol acetate 0.1 mg in 24 [usp'u] - femring therapy is indicated in the: 1. treatment of moderate to severe vasomotor symptoms due to menopause. 2. treatment of moderate to severe vulvar and vaginal atrophy due to menopause. femring should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active arterial thromboembolic disease (for example, stroke and myocardial infarction) or a history of these conditions. - known liver dysfunction or disease. - known or suspected pregnancy.
femring- estradiol acetate ring
millicent us, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - femring is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to femring - known liver impairment or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy femring should not be used during pregnancy [ see contraindications (4) ] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. femring should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast
femring 50 microgrammes/24 heures, système de diffusion vaginal
galen limited - estradiol - système - 50 microgrammes/24 heures pendant trois mois - de diffusion vaginal composition pour un réservoir de médicament > estradiol : 50 microgrammes/24 heures pendant trois mois . sous forme de : acetate d'estradiol 12,40 mg - estrogènes naturels et hemisynthétiques, non associes.
femring estradiol acetate
allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d
femarelle® recharge (uzlāde) (2016.) kapsula
se-cure pharmaceuticals ltd. - kapsula
femarelle® unstoppable (neapturama) (2016.) kapsula
se-cure pharmaceuticals ltd. - kapsula
femarelle® rejuvenate (atjaunošanās) (2016.) kapsula
se-cure pharmaceuticals ltd. - kapsula
femarelle® kapsula
se-cure pharmaceuticals ltd., haarava st., unitronics bldg., airport city 70100 - kapsula
femring 50 mikrogram/24 timmar vaginalinlägg
galen ltd - estradiolacetat - vaginalinlägg - 50 mikrogram/24 timmar - estradiolacetat 12,4 mg aktiv substans - Östradiol